R

    Revolution Medicines Inc (RVMD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $205.57
    -2.31 (-1.11%)

    Market Cap: $44.56B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    19%(5/27)
    Avg Surprise
    -68.02%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-2.45
    Range$-3.26 - $-2.12
    17 analysts
    EPS RevisionsNo revisions (7d)
    0
    9
    30d
    EPS Estimate Drift
    90d ago$-1.96+20.1%
    60d ago$-1.97+19.7%
    30d ago$-1.99+18.9%
    7d ago$-2.46-0.0%
    Current$-2.45
    Revenue Consensus
    $9M
    Range$0 - $50M
    17 analysts
    Dec 31, 2026
    EPS Consensus$-3.42
    Range$-6.00 - $-2.00
    20 analysts
    Revenue Consensus
    $94M
    Range$-26932530 - $354M
    18 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-3.42---
    Sep 26EST
    		-$-2.45---
    Jun 26
    		$-2.34$-1.93-21.24%Miss-78.6%
    Mar 26
    		$-2.29$-1.84-24.46%Miss-102.7%
    Dec 25
    		$-1.86$-1.58-17.72%Miss-66.1%
    Sep 25
    		$-1.61$-1.39-15.83%Miss-71.3%
    Jun 25
    		$-1.31$-1.12-16.96%Miss-61.7%
    Mar 25
    		$-1.13$-1.06-6.60%Miss-61.4%
    Dec 24
    		$-1.12$-0.96-16.12%Miss+1.8%
    Sep 24
    		$-0.94$-0.88-6.82%Miss+5.1%
    Jun 24
    		$-0.81$-0.76-6.58%Miss+12.0%
    Mar 24
    		$-0.70$-0.72+2.78%Beat+2.8%
    Dec 23
    		$-1.14$-0.88-29.55%Miss-81.0%
    Sep 23
    		$-0.99$-1.00+1.00%Beat-13.8%
    Jun 23
    		$-0.92$-0.82-12.20%Miss-12.2%
    Mar 23
    		$-0.72$-0.80+10.00%Beat+7.7%
    Dec 22
    		$-0.63$-0.82+23.17%Beat+11.3%
    Sep 22
    		$-0.87$-0.85-2.35%Miss-20.8%
    Jun 22
    		$-0.82$-0.84+2.38%Beat-36.7%
    Mar 22
    		$-0.78$-0.77-1.30%Miss-47.2%
    Dec 21
    		$-0.71$-0.64-10.94%Miss-36.5%
    Sep 21
    		$-0.72$-0.62-16.13%Miss-71.4%
    Jun 21
    		$-0.60$-0.56-7.14%Miss-30.4%
    Mar 21
    		$-0.53$-0.52-1.92%Miss+28.4%
    Dec 20
    		$-0.52$-0.38-36.84%Miss+92.0%
    Sep 20
    		$-0.42$-0.40-5.00%Miss-13.5%
    Jun 20
    		$-0.46$-0.37-24.32%Miss-
    Mar 20
    		$-0.74$-0.36-105.56%Miss-
    Dec 19
    		$-6.52$-0.41-1490.24%Miss-
    Sep 19
    		$-0.37$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-25.38EV/EBITDA-9.71x
    Price/FCF-35.19xFCF Yield-2.84%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-79.10%ROIC-46.15%
    Financial Health
    Debt/Equity0.19xInterest Coverage-35.66x
    Current Ratio11.38xQuick Ratio11.38x
    Trading Statistics
    Beta1.40Avg Volume1.84M
    52-Week High$224.3152-Week Low$37.88

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$212.49
    SMA 20$207.70
    SMA 50$193.65
    SMA 200$131.19
    EMA 10$210.37
    EMA 20$206.39
    EMA 50$192.38
    EMA 200$139.87

    MACD

    Line: 6.15Signal: 7.20Hist: -1.05

    ADX

    ADX: 27.4+DI: 24.0-DI: 29.3

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down8.0
    PSAR$199.92

    Bollinger Bands

    Upper Band$221.50
    Lower Band$193.91
    %B Position1328%(Upper)
    Band Width0.42

    RSI (14-Day)

    Neutral
    52.3

    Momentum Oscillators

    Stoch %K49.7
    Stoch %D64.7
    Williams %R-73.7
    ROC (10d)-3.0%
    Momentum-6.43
    CCI (20d)-31.5
    MFI (14d)43.9

    Volatility Measures

    ATR (14d)$8.60(4.2%)
    StdDev (20d)6.90
    Hist Vol40.4%(High)

    Volume Flow

    VWAP$204.37
    OBV116.7M
    AD Line70.7M
    CMF (20d)0.264

    Volume Metrics

    Avg Vol (20d)1.8M
    Vol Ratio1.2x
    VWMA (20d)$208.81

    Pivot Points

    R3$233.33
    R2$227.41
    R1$217.65
    Pivot Point$211.73
    S1$201.97
    S2$196.05
    S3$186.29

    Advanced Oscillators

    TSI24.08
    Ultimate Osc57.1
    KST118.82

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$261.59M$0$0$0$742,000$0
    Cost of Revenue$0$0$4.70M$0$0$0$188.10M$0$0$0$136.58M$0
    Gross Profit$0$0$-4,702,000$0$0$0$-188,096,000$0$0$0$742,000$0
    Operating Expenses$505.13M$445.22M$361.63M$315.27M$264.71M$240.76M$216.31M$175.71M$156.64M$140.86M$180.72M$123.25M
    R&D$394.92M$343.97M$294.94M$262.51M$224.13M$205.75M$187.52M$151.75M$134.93M$118.02M$148.48M$107.73M
    SG&A$110.21M$101.25M$66.68M$52.76M$40.58M$35.01M$28.79M$23.96M$21.71M$22.84M$32.24M$15.51M
    Operating Income$-505,132,000$-445,222,000$-361,626,000$-315,269,000$-264,714,000$-240,760,000$-216,310,000$-175,712,000$-156,643,000$-140,859,000$-179,983,000$-123,248,000
    Interest Income$35.58M$19.51M$21.29M$22.08M$22.40M$24.91M$21.23M$20.41M$21.49M$23.76M$18.98M$10.95M
    Interest Expense$23.78M$12.20M$3.27M$11.43M$867,000$0$0$0$-16,000$0$0$0
    Income Before Tax$-644,371,000$-453,816,000$-364,892,000$-305,206,000$-247,787,000$-213,416,000$-195,322,000$-156,288,000$-133,233,000$-116,003,000$-161,194,000$-112,301,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$343,000$-3,867,000
    Net Income$-644,371,000$-453,816,000$-364,892,000$-305,206,000$-247,787,000$-213,416,000$-194,569,000$-156,288,000$-133,233,000$-116,003,000$-161,537,000$-108,434,000
    EBITDA$-656,002,000$-459,581,000$-374,132,000$-317,240,000$-273,265,000$-244,432,000$-227,562,000$-182,146,000$-162,841,000$-152,244,000$-185,946,000$-126,247,000
    EBIT$-656,169,000$-460,893,000$-374,280,000$-315,861,000$-269,324,000$-238,331,000$-222,123,000$-175,430,000$-154,736,000$-139,763,000$-180,171,000$-123,248,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RVMD

    News

    Revolution Medicines(RVMD.US) Officer Sells US$17.99 Million in Common Stock

    An officer at Revolution Medicines (RVMD.US) has sold common stock totaling US$17.99 million. This transaction indicates a significant insider sale at the company.

    Moomoo•8/25/26•
    Bearish

    Revolution Medicines (RVMD) GC trades 56K shares via 10b5-1 plan

    Revolution Medicines' General Counsel, Jeff Cislini, exercised stock options for 56,280 shares and subsequently sold 56,894 shares of common stock on August 21, 2026. These transactions, executed under a Rule 10b5-1 trading plan, involved sales at weighted average prices ranging from approximately $206.76 to $212.74 per share. Cislini still holds 43,514 restricted stock units after these transactions.

    Stock Titan•8/25/26•
    Somewhat-Bearish

    Revolution Medicines (RVMD) CEO trades stock under preset 10b5-1 plan

    Revolution Medicines (RVMD) CEO Mark A. Goldsmith exercised options for 80,000 shares and subsequently sold 86,000 shares of common stock, including through revocable trusts, under a pre-arranged Rule 10b5-1 trading plan adopted on May 22, 2026. The sales occurred at weighted average prices between $206.78 and $212.74, while the options were exercised at $4.73 per share. Goldsmith's reported holdings still include 182,938 restricted stock units.

    Stock Titan•8/25/26•
    Neutral

    ETFs Investing in Revolution Medicines, Inc. Stocks

    This article lists various Exchange Traded Funds (ETFs) that hold stocks of Revolution Medicines, Inc. For each ETF, it provides details such as market value, weight of Revolution Medicines, Inc. stock, issuer, management style, focus, expense ratio, AUM, price, change, relative volume, and 3-year NAV total return. The ETFs cover a range of market segments including total market, small-cap, mid-cap, large-cap, health care, and biotechnology.

    TradingView•8/22/26•
    Neutral

    Revolution Medicines (NASDAQ: RVMD) director plans August stock sale after June $1.6M trade

    Revolution Medicines, Inc. director Mark A. Goldsmith plans to sell 80,000 shares of common stock on August 21, 2026, with an aggregate market value of approximately $16.9 million. This planned sale is linked to the exercise of stock options. In the preceding three months, Goldsmith sold 10,020 shares on June 16, 2026, for proceeds of over $1.5 million.

    Stock Titan•8/22/26•
    Neutral

    Frequently Asked Questions About RVMD

    Does RVMD pay dividends?
    Revolution Medicines Inc (RVMD) does not currently pay a regular dividend.
    What is RVMD's market cap?
    Revolution Medicines Inc (RVMD) has a market capitalization of $44.56B with a current stock price of $205.57.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In